• Q3 2025 unaudited group revenue of approximately $206 million, up 53% year-over-year
• FY 2025 revenue guidance increased to $800 million to $820 million
• Gozellix® now fully reimbursed by CMS, Illuccix® approved in 19 European markets and UK

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) reported its Q3 2025 commercial and operational performance, with key highlights including:- Q3 2025 unaudited group revenue of approximately $206 million, up 53% year-over-year- FY 2025 revenue guidance increased to $800 million to $820 million, from the previous guidance of $770 million to $800 million- Gozellix® now fully reimbursed by Centers for Medicare and Medicaid Services (CMS), with a Level II HCPCS code and Transitional Pass-Through (TPT) payment status effective 1 October 2025- Illuccix® now approved in 19 European markets and the United Kingdom (UK); commercial launch has commenced in the UK, Germany, France, Finland, Sweden, Norway and Denmark- First patients dosed in the BiPASS™ trial of MRI + PSMA-PET for the diagnosis and detection of prostate cancer- ProstACT® Global Phase 3 trial - Part 2 open for enrollment in Australia, New Zealand, Canada, China, Singapore, Türkiye and JapanThe company also provided updates on its therapeutic pipeline, including the TLX591, TLX250, TLX101, and TLX090 programs, as well as progress on its Precision Medicine business and manufacturing solutions.

Telix increases FY 2025 revenue guidance to $800 million to $820 million. The guidance reflects revenue from PSMA imaging (Illuccix and Gozellix) product sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS.